PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma

Official title

PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma: a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Overview

This is a prospective, multicenter, phase II study, in elderly patients affected by Mantle cell lymphoma (MCL) defined as unfit/frail according to Simplified Geriatric Assessment (sGA) and previously untreated. Patients will receive a treatment with Pirtobrutinib monotherapy until tumor progression, unacceptable adverse event, or patient decision for interruption.

Detailed description

After providing written informed consent, patients will be evaluated for eligibility during a 28-day screening period. Patients will receive pirtobrutinib at a starting dose of 200 mg once daily (2 tablets q.d.). All treatment will be administered orally, and a cycle will be defined as 28 days in length and should be maintained regardless of dose interruptions. Treatment is meant to be administered until tumor progression, unacceptable adverse event, or patient decision for interruption.

Responses shall be assessed at month +3, +6 after start of treatment and then every 6 months using the radiologic method of tumor assessment consistent throughout the study and aligned with the baseline method (CT scan or ultrasound echography are acceptable). Positron Emission Tomography (PET) scan is mandatory at baseline and at month +3 after start of treatment to establish tumor response.

Interventions

• Drug Pirtobrutinib
  Patients will receive pirtrobrutinib at a starting dose of 200 mg once daily (q.d). All treatment will be administered orally and a cycle will be defined as 28 days in length and should be maintained regardless of dose interruptions. Treatment is meant to be administered until tumor progression, unacceptable adverse event, or patient decision for interruption.

Primary outcome measures

• Progression Free Survival (PFS) [Time frame: 48 months]

Secondary outcome measures (10)

• Overall response rate (ORR) [Time frame: 48 months]
• Complete response rate (CRR) [Time frame: 48 months]
• Overall survival (OS) [Time frame: 48 months]
• Event free survival (EFS) [Time frame: 48 months]
• Duration of response (DOR) [Time frame: 48 months]
• Drop-out rate [Time frame: 48 months]
• Rate of treatment discontinuation due to Adverse Event (AE) or treatment intolerance. [Time frame: 48 months]
• Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) [Time frame: 48 months]
• Health-Related Quality of Life Assessed by the EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire [Time frame: 48 months]
• Health-Related Quality of Life Assessed by the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Questionnaire [Time frame: 48 months]

Eligibility criteria

Inclusion criteria

• Histologically documented diagnosis of nodal and extranodal mantle cell lymphoma (MCL) as defined in the 2022 edition of the World Health Organization (WHO) classification
• Availability of biopsy material for central pathology revision and mutational analysis including TP53 (Tumor Protein p53) mutations
• Age ≥ 70 years
• Previously untreated MCL
• Active disease in need of treatment according to clinical practice (patients with leukemic with symptomatic leukemic non nodal disease may be included)
• Ineligible to standard full-dose induction therapy (i.e. BR, R-CHOP, VR-CAP, RBAC500)
• sGA assessment performed before starting treatment

FRAIL patients defined as follows:

• Age ≥ 80 years
• Activities of Daily Living (ADL) <6 residual functions and/or
• Instrumental Activities of Daily Living (IADL) <8 residual functions and/or
• Cumulative Illness Rating Scale (CIRS): ≥ 1 comorbidity of grade 3-4 or ≥ 5 comorbidities of grade 2

UNFIT patients defined as follows:

• Age ≥ 80 years:
• ADL 6 residual functions and
• IADL 8 residual functions and
• CIRS 0 comorbidities of grade 3-4 and <5 comorbidities of grade 2

or

• Age < 80 years:
• ADL < 5 residual functions and/or
• IADL < 6 residual functions and/or
• CIRS ≥ 1 comorbidity of grade 3-4 or >8 comorbidities of grade 2
• Ann Arbor Stage I - IV
• At least one bi-dimensionally measurable lesion defined as > 1.5 cm in its largest dimension on CT scan
• Eastern Cooperative Oncology Group (ECOG) performance status of 0- 2
• Adequate hematologic function (unless caused by bone marrow infiltrate), defined as follows:

• Hemoglobin ≥ 8 g/dL (independent of transfusions within 7 days of screening assessment)
• White blood cells (WBC) > 2500/mmc with polymorphonuclear (cells) PMN≥750/ mmc) (independent of growth factor support within 7 days of screening assessment)
• Platelets count ≥ 50000/mmc (independent of transfusions within 7 days of screening assessment)
• Adequate renal function:

• Creatinine clearance ≥ 30 mL/min or
• Serum creatinine ≤ 2.5 mg /dL
• Adequate coagulation, defined as activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) and prothrombin (PT) or (international normalized ratio (INR) not greater than 1.5 x upper limit of normal (ULN)
• Adequate hepatic function:

• Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) ≤ 3 x the ULN or ≤ 5 x ULN with documented liver involvement
• Total bilirubin ≤ 1.5 x ULN or ≤ 3 x ULN with documented liver involvement and/or due to Gilbert's Disease
• Ability and willingness to comply with the study protocol procedure
• Life expectancy > 6 months
• The patient is able to take oral medications
• The patient must give written informed consent
• Male subjects must use highly effective contraception during sexual contact with a pregnant female or a female of childbearing potential from the start of study treatment and continuing for at least 3 months after the last dose of pirtobrutinib

Exclusion criteria

Patients who meet any of the following criteria are not eligible to enroll:

• Candidate to watch and wait due to indolent presentation
• Leukemic non-nodal MCL that has stable asymptomatic disease should not be included in this study
• Histological diagnosis different from MCL or leukemic non-nodal MCL
• Fit patients according to sGA eligible to standard full dose therapy
• Candidate or eligible to full-dose Bendamustine+Rituximab (BR), Rituximab + Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine) e Prednisone (R-CHOP), bortezomib, rituximab, cyclophosphamide, doxorubicin, prednisone (VR-CAP), Rituximab, Bendamustine, Cytarabine (RBAC500) or any other full dose intensive chemotherapy
• Suspect or clinical evidence of central nervous system (CNS) involvement by lymphoma
• Contraindication to the use Bruton Tyrosine Kinase Inhibitor (BTKi)
• HBsAg positivity; HBsAg-negative patients with anti-hepatitis B core antigen (HBc) antibody can be enrolled if Hepatitis B Virus (HBV)-DNA are negative and prophylactic antiviral treatment is provided
• HIV positivity
• Active herpes zoster infection; previously infected patients is accepted only with concomitant treatment with Valacyclovir
• Major surgery within 4 weeks prior to investigation treatment
• Any history of other malignancies unless in remission and with life expectancy > 2 years prior to study entry except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer
• Patients who experienced grade ≥ 3 arrhythmia.
• History of severe bleeding diathesis (major bleeding event) Note: Major bleeding is defined as bleeding having one or more of the following features: potentially life-threatening bleeding with signs or symptoms of hemodynamic compromise; bleeding associated with a decrease in the hemoglobin level of at least 2 g per deciliter; or bleeding in a critical area or organ (e.g., retroperitoneal, intraarticular, pericardial, epidural, or intracranial bleeding or intramuscular bleeding with compartment syndrome)
• History of stroke or intracranial hemorrhage within 6 months of investigation treatment
• History of Chimeric Antigen Receptor T-cell therapy (CAR-T) within 60 days of investigation treatment or presence of any of the following, regardless of prior Stem Cell Transplantation (SCT) and/or CAR-T therapy timing:

• active graft versus host disease (GVHD);
• cytopenia from incomplete blood cell count recovery post-transplant;
• need for anti-cytokine therapy for toxicity from CAR-T therapy; residual symptoms of neurotoxicity > Grade 1 from CAR-T therapy;
• ongoing immunosuppressive therapy (> 20 mg prednisone or equivalent daily)
• Evidence of any severe active acute or chronic infection
• Hepatitis C virus (HCV): positive hepatitis C antibody. If positive hepatitis C antibody result, HCV-RNA is required. Only patients with HCV-RNA negative are accepted.
• Known active cytomegalovirus (CMV) infection. Unknown or negative status are eligible
• Clinically significant active malabsorption syndrome or other conditions likely to affect gastrointestinal (GI) absorption of the study drug
• Evidence of other clinically significant uncontrolled condition(s) including but not limited to, uncontrolled systemic bacterial, viral, fungal or parasitic infection (except for fungal nail infection), or other clinically significant active disease process which in the opinion of the investigator and medical monitor may pose a risk for patient participation. Screening for chronic conditions is not required
• Active uncontrolled auto-immune cytopenia (e.g., AutoImmune Hemolytic Anemia \[AIHA\], Idiopathic Thrombocytopenic Purpura \[ITP\]) for which new therapy was introduced or existing therapy was escalated within the 4 weeks prior to study enrollment to maintain adequate blood counts
• Significant cardiovascular disease defined as:

• unstable angina or acute coronary syndrome within the past 2 months prior to study enrollment
• history of myocardial infarction within 3 months prior to study enrollment or
• documented left ventricular ejection fraction (LVEF) by any method of ≤ 40% in the 12 months prior to study enrollment
• ≥ Grade 3 New York Heart Association (NYHA) functional classification system of heart failure
• Uncontrolled or symptomatic arrhythmias
• Prolongation of the QT interval corrected for heart rate (QTcF) > 470 msec. QTcF is calculated using Fridericia's Formula (QTcF): QTcF = QT/(RR0.33):

• Correction of suspected drug-induced QTcF prolongation can be attempted at the investigator's discretion and only if clinically safe to do so with either discontinuation of the offending drug or switch to another drug not known to be associated with QTcF prolongation.
• Correction for underlying bundle branch block (BBB) allowed. Note: Patients with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker
• Any other co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent
• Absence of caregivers in non-autonomous patients
• Need of anticoagulation with warfarin or another vitamin K antagonist
• Vaccination with live vaccine within 28 days prior to investigation treatment
• Have a known hypersensitivity to any of the excipients of Pirtobrutinib or to any intended study medications

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

Italy · 20 centers

• IRCCS Istituto Romagnolo per lo studio dei Tumori "Dino Amadori" - IRST S.R.L. - Ematologi — Meldola
• Istituto Clinico Humanitas - U.O. Ematologia — Rozzano
• AOU Ospedali Riuniti - Clinica di Ematologia — Ancona
• Azienda Ospedaliera S.Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico — Avellino
• Nuovo Ospedale degli Infermi - SSD Ematologia — Biella
• Policlinico S.Orsola-Malpighi - Istituto di Ematologia "Seragnoli" — Bologna
• ASST Spedali Civili di Brescia - Ematologia — Brescia
• Azienda Ospedaliera Universitaria Policlinico - S. Marco - UOC di Ematologia — Catania
• … and 12 more centers

Identifiers

NCT: NCT07207785 · FIL_PUMA

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗